Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

People who were hospitalised with COVID-19 and continued to experience symptoms five months later, show limited further recovery one year after hospital discharge according to the latest results of a major national study.

© Shutterstock

The latest findings of the PHOSP-COVID study, which involves several researchers from the University of Oxford including Professor Ling-Pei Ho of the MRC Human Immunology Unit (MRC HIU), have been published on the medRxiv pre-print website.

Researchers from 53 institutions and 83 hospitals across the UK assessed 2,230 adults who had been hospitalised with COVID-19. The researchers found that one year after hospital discharge, fewer than 3 in 10 patients on the study reported they felt fully recovered, largely unchanged from 2.5 in 10 at five months. The most common ongoing symptoms were fatigue, muscle pain, physically slowing down, poor sleep and breathlessness.

Participants felt their health-related quality of life remained substantially worse one year after hospital discharge, compared to pre-COVID. This suggests the physical and mental health impairments reported in the study are unlikely to be pre-existing conditions.

Professor Ling-Pei Ho, a Group Leader at the MRC HIU, MRC Weatherall Institute of Molecular Medicine said: “PHOSP-COVID research teams have also identified some differences in the blood samples of patients who are still experiencing the long-term physical and cognitive effects of their COVID-19 hospital admission. These might indicate possible underlying mechanisms, and help us identify existing medicines that target these mechanisms to help these patients.

“Oxford has been a key contributor to this research, and it has been a massive team effort from the Long COVID clinic, BRC Integrative Respiratory Physiology Clinic, Oxford Respiratory Trials Unit, and research laboratories in Human Immunology Unit and Respiratory. Every patient who gave their time has contributed to this huge landmark study, which will continue to inform how we treat and support our post-COVID patients going forward.”

The PHOSP-COVID study, led by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre (BRC), has been given urgent public health research status by the Department of Health and Social Care. Around 10,000 patients are expected to take part in the study, making it one of the largest comprehensive studies in the world to understand and improve the health of survivors after hospitalisation from COVID-19. As well as the NIHR, the PHOSP-COVID study is funded by the MRC-UK Research and Innovation (UKRI).

 

 

 

Similar stories

Beyond Boundaries at the Oxford Imaging Symposium

Held on 29th September 2022, the symposium brought together researchers from across the world to present the latest applications of advanced imaging.

Anjali Kusumbe receives the RMS Life Sciences Medal

The Royal Microscopical Society awards celebrate the best in microscopy, recognising those making a special contribution to microscopy, cytometry and imaging.

Fundraising for award in memory of Dr Ling Felce

The Ling Felce award will promote cross-disciplinary excellence in bioinformatics.

Study of T-cell receptor activation leads to surprising discovery

A study from Davis Group is the first to describe the structure of the T-cell receptor when bound to an activating ligand. The findings shed light on an important trigger in the immune system, and suggest a completely new process by which cell receptors can be activated.

Biotech spinout MiroBio acquired by Gilead Sciences for ~£332m

Co-founded by Prof. Simon Davis, MiroBio focuses on developing therapeutics for inflammatory diseases.

New study shines light on the complex mechanisms of Fetal Growth Restriction in pregnancy

The paper, published in Nature Communications reveals key genes involved in the common developmental disease.